# Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer

> **NCT00472459** · PHASE3 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 82 (actual)

## Conditions studied

- Actinic Keratosis
- Warts
- Basal Cell Carcinoma
- Bowens Disease
- Squamous Cell Carcinoma

## Interventions

- **PROCEDURE:** Photodynamic therapy with Metvix 160 mg/g cream

## Key facts

- **NCT ID:** NCT00472459
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07-25
- **Primary completion:** 2004-09-23
- **Final completion:** 2006-07-14
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2025-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00472459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00472459, "Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00472459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*